News and Announcements

Cellmid Signs Midkine Diagnostic Agreement

Published February 11, 2013 10:47AM UTC
Publisher Wholesale Investor
Categories Company Updates

Option to License agreement signed for the Company’s diagnostic technology
Cellmid to receive an upfront option fee and supply its diagnostic antibodies
Multiple cancer diagnostic products are expected to be developed
Agreement further validates Cellmid’s midkine diagnostic technology

SYDNEY, Monday, 11 February 2013: Cellmid Limited (ASX: CDY) has signed an important option agreement with listed Japanese company Fujikura Kasei Co Ltd, a major supplier of latex particles used in medical diagnostics.

Under the terms of the Option to License agreement Cellmid will supply its proprietary anti-midkine diagnostic antibodies for validation on Fujikura’s latex platform. Cellmid will receive an initial fee and a further payment should Fujikura elect to exercise its license option. Cellmid will also receive royalties on any future midkine diagnostic products sold by Fujikura.

To read full ASX announcement, please download the document below.

Company Updates

View All

Capital Insights

Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026

Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]

Capital Insights

The control layer for the electrified home

THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]

Capital Insights

500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market

In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]

View All